Assay As App? BD Launches BD Max With Open Platform "Smartphone" Model
This article was originally published in The Gray Sheet
Executive Summary
BD Diagnostics hopes its new BD Max molecular testing platform will create a smartphone "app"-type model for developing new assays and open up profitable partnering opportunities for the firm.
You may also be interested in...
BD Gets First Partnered Assay Released For Open-Platform BD Max
BD unveiled BD Max last year as the first fully-automated molecular diagnostics analyzer with an open platform, signaling plans for a smartphone-style “app” business model for molecular diagnostics.
New Products In Brief
Recent approvals and market launches include St. Jude’s ViewFlex Xtra catheter for cardiac imaging, Myoscience’s cold therapy pain treatment device and Spacelabs’ Blease900 ventilator for anesthesia.
BD Closes $275 Million HandyLab Buy; New HAI Platform Will Launch In 2011
BD will launch its BD Max molecular diagnostic system in late 2011 or early 2012, combining its existing assays for health care-associated infections with its newly acquired HandyLab Jaguar integrated testing platform technology, according to the company